Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, discusses ongoing and upcoming clinical trials for patients with bladder cancer, including AMBASSADOR (NCT03244384), CheckMate 274 (NCT02632409), IMvigor010 (NCT02450331), NILE (NCT03682068), and EV-302 (NCT04223856). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.